Compare Eli Lilly And Co (LLY) vs Cloudflare Inc (NET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Cloudflare Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Cloudflare Inc trades at $361 (market cap $121.74B). The key difference: Eli Lilly And Co is far larger — about 8.5× Cloudflare Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Cloudflare Inc for 61 Days on average.
| LLY | NET | |
|---|---|---|
Market Cap | $1.04T | $121.74B |
Volume | 3,064,878 | 2,433,002 |
Sector | Health | Technology |
52-Week High | $1.28K | $361.00 |
52-Week Low | $799.57 | $160.16 |
Typical Hold Time | 93 Days | 61 Days |
Enterprise Value | $1.09T | $121.11B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Cloudflare (NET) trades at $341.70, down 0.33% with a bullish technical signal despite negative profitability metrics. The stock shows strong revenue growth from $975M in 2022 to $2.17B in 2025, though net losses persist. Recent product launches including Cloudflare Basin and security partnerships with Deutsche Telekom highlight innovation momentum. Analyst consensus remains strongly bullish with 70.7% buy ratings and a $331.10 price target.
Investment outlook balances high growth potential against valuation concerns. The company's expanding platform and AI security positioning offer upside, but negative margins and premium valuations (P/S 47.88) create risk. Key catalysts include Q3 earnings beat potential and enterprise adoption, while competitive pressure and execution challenges pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
